PROKIDNEY CORP. Enters Material Definitive Agreement
Ticker: PROK · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1850270
| Field | Detail |
|---|---|
| Company | Prokidney Corp. (PROK) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $19.1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, company-update
TL;DR
ProKidney Corp. just signed a big deal, filing an 8-K on Oct 17, 2025.
AI Summary
On October 17, 2025, PROKIDNEY CORP. (formerly Social Capital Suvretta Holdings Corp. III) entered into a material definitive agreement. The company, incorporated in Delaware, is involved in Biological Products, excluding diagnostics, and is headquartered in Winston-Salem, NC.
Why It Matters
This filing indicates a significant development for PROKIDNEY CORP., likely involving a new contract, partnership, or acquisition that could impact its business operations and future growth.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement is a significant event that can introduce new risks or opportunities, requiring further analysis of the agreement's terms.
Key Numbers
- 001-40560 — SEC File Number (Identifies the company's filing history with the SEC.)
- 98-1586514 — IRS Employer Identification No. (Unique tax identification number for the company.)
Key Players & Entities
- PROKIDNEY CORP. (company) — Registrant
- Social Capital Suvretta Holdings Corp. III (company) — Former Company Name
- October 17, 2025 (date) — Date of Report
- 2000 Frontis Plaza Blvd. Suite 250, Winston-Salem, North Carolina 27103 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by PROKIDNEY CORP. on October 17, 2025?
The filing states that PROKIDNEY CORP. entered into a material definitive agreement on October 17, 2025. Specific details of the agreement are not provided in this summary but would be found in the full document.
When was PROKIDNEY CORP. formerly known as?
PROKIDNEY CORP. was formerly known as Social Capital Suvretta Holdings Corp. III.
What is the principal executive office address for PROKIDNEY CORP.?
The principal executive offices of PROKIDNEY CORP. are located at 2000 Frontis Plaza Blvd. Suite 250, Winston-Salem, North Carolina 27103.
What is the Standard Industrial Classification code for PROKIDNEY CORP.?
The Standard Industrial Classification code for PROKIDNEY CORP. is 2836, which corresponds to Biological Products (excluding diagnostics).
What is the SEC file number for PROKIDNEY CORP.?
The SEC file number for PROKIDNEY CORP. is 001-40560.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2025-10-17 16:32:02
Key Financial Figures
- $0.0001 — hich registered Class A common stock, $0.0001 par value per share PROK The Nasdaq
- $19.1 million — sboro, North Carolina for approximately $19.1 million in cash. The Agreement contains customa
Filing Documents
- prok-20251017.htm (8-K) — 41KB
- 0001193125-25-242565.txt ( ) — 147KB
- prok-20251017.xsd (EX-101.SCH) — 25KB
- prok-20251017_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC ("Acquisition Sub"), entered into a purchase and sale agreement with Williams Development Group, LLC (the "Williams Purchase Agreement") to sell the Company's property located in Greensboro, North Carolina. The Williams Purchase Agreement was subsequently terminated and, on October 17, 2025, the Company, through Acquisition Sub, entered into a new purchase and sale agreement with Northpoint Development, LLC (the "Northpoint Agreement") to sell the Company's real property located in Greensboro, North Carolina for approximately $19.1 million in cash. The Agreement contains customary representations and closing conditions for a transaction of this type. The foregoing description of the Northpoint Agreement is qualified in its entirety by reference to the full text of such agreement, which the Company intends to file as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: October 17, 2025 By: /s/ Todd Girolamo Name: Todd Girolamo Title: Chief Legal Officer